Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 13.89 is 134% above its 4-year average of 5.95, near the high end of its 4-year range (0.00–14.16).
As of the fiscal period ended Tuesday, June 30, 2026. 35.92% above its 12-month average of 10.22.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.89.
CURRENT RATIO
13.89
CURRENT RATIO AVG TTM
10.22
CURRENT RATIO AVG 3Y
7.46
CURRENT RATIO AVG 5Y
N/A
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+35.92%
CURRENT VS 3Y AVG
+86.16%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.40
median of 650 covered companies
CURRENT VS SECTOR MEDIAN
+309.03%
vs the sector median at left
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$258.73M
Current Ratio
13.89
TTM Avg
10.22
3Y Avg
7.46
5Y Avg
N/A
Market Cap
$256.22M
Current Ratio
8.28
TTM Avg
3.73
3Y Avg
7.03
5Y Avg
8.20
Market Cap
$255.48M
Current Ratio
4.48
TTM Avg
4.80
3Y Avg
5.23
5Y Avg
5.23
Market Cap
$261.43M
Current Ratio
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
Market Cap
$265.50M
Current Ratio
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
Market Cap
$264.72M
Current Ratio
8.88
TTM Avg
8.27
3Y Avg
7.75
5Y Avg
6.94
Market Cap
$267.45M
Current Ratio
4.50
TTM Avg
8.35
3Y Avg
6.79
5Y Avg
6.91
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $258.73M | 13.89 | 10.22 | 7.46 | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | 8.28 | 3.73 | 7.03 | 8.20 |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.48M | 4.48 | 4.80 | 5.23 | 5.23 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 15.82 | 24.04 | 14.70 | 12.06 |
| AC Immune S.A. (ACIU)vs › | $262.66M | 0.93 | 1.36 | 5.78 | 8.29 |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | 24.26 | 16.09 | 10.56 | 7.83 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $265.50M | 16.00 | 13.11 | 8.33 | 7.81 |
| OraSure Technologies, Inc. (OSUR)vs › | $264.72M | 8.88 | 8.27 | 7.75 | 6.94 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.45M | 4.50 | 8.35 | 6.79 | 6.91 |
| Invivyd, Inc. (IVVD)vs › | $247.23M | 5.87 | 4.43 | 7.10 | 7.89 |
Current Ratio
13.89
Quick Ratio
13.89
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 13.89 |
| 2026-03-31 | 14.16 |
| 2025-12-31 | 11.21 |
| 2025-09-30 | 7.40 |
| 2025-06-30 | 4.43 |
| 2025-03-31 | 3.42 |
| 2024-12-31 | 5.52 |
| 2024-09-30 | 5.95 |
| 2024-06-30 | 9.38 |
| 2024-03-31 | 9.16 |
| 2023-12-31 | 7.21 |
| 2023-09-30 | 1.69 |
| 2023-06-30 | 3.57 |
| 2023-03-31 | 4.47 |
| 2022-12-31 | 5.58 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
